Strategic Collaboration Between Codexis and Nitto Denko Avecia
In an exciting development for the field of therapeutic manufacturing, Codexis, Inc. (NASDAQ: CDXS), a prominent provider of enzymatic solutions designed for scalable therapeutic development, has entered into a pivotal evaluation agreement with Nitto Denko Avecia, a leading contract development and manufacturing organization (CDMO) that specializes in oligonucleotide therapeutics.
Evaluating the ECO Synthesis Manufacturing Platform
Through this partnership, Nitto Denko Avecia will conduct an evaluation of Codexis’ ECO Synthesis Manufacturing Platform. This innovative platform is designed to replace traditional oligonucleotide synthesis methods with a more flexible and efficient enzyme-catalyzed approach. This collaboration sets the stage for potential licensing discussions and broader market adoption of the ECO Synthesis platform, which aims to enhance efficiency in therapeutic development.
Industry Leaders’ Insights
Stephen Dilly, MBBS, PhD, who serves as the Chairman and CEO of Codexis, expressed enthusiasm regarding this partnership. He stated, "We are excited to partner with Nitto Denko Avecia, a recognized leader in therapeutic oligonucleotide manufacturing. This collaboration represents a significant milestone toward expanding the reach of our ECO Synthesis Manufacturing Platform, through best-in-class CDMO collaborations."
On the other side, Tammy Cooper, President at Nitto Denko Avecia, highlighted the company's commitment to advancing oligonucleotide manufacturing. According to Tammy, "Exploring Codexis' ECO Synthesis Manufacturing Platform reflects our commitment to pioneering next-generation technologies that can redefine scalability, sustainability, and innovation in therapeutic development. This collaboration aligns with our mission to deliver high-quality therapeutics to our partners and patients worldwide."
Combining Forces for Enhanced Therapeutic Development
The union of Codexis’ technological advancements with Nitto Denko Avecia’s expertise in oligonucleotide manufacturing marks a significant step in advancing scalable and sustainable therapeutic siRNA production. By leveraging the unique capabilities of both companies, this collaboration aims to revolutionize therapeutic manufacturing and make groundbreaking developments more accessible.
About Codexis, Inc.
Codexis is at the forefront of redefining possibilities in therapeutic development and manufacturing, driving an enzymatic technology revolution with efficient and commercially validated solutions. The company’s platforms are consistently setting new benchmarks compared to conventional methods, enabling the exploration of therapeutic potential that was previously unachievable. Thanks to its proprietary technologies and exceptional scientific expertise, Codexis fosters long-lasting partnerships aimed at propelling progress across the healthcare landscape.
About Nitto Denko Avecia, Inc.
Nitto Denko Avecia, Inc. stands out as a leader in the development and manufacturing of oligonucleotide therapeutics. With operations extending across multiple locations, the company offers comprehensive solutions suited for preclinical and commercial applications, having successfully manufactured over 1,500 oligonucleotide sequences as part of an extensive late-phase portfolio.
Frequently Asked Questions
What is the main goal of the Codexis and Nitto Denko collaboration?
The collaboration focuses on evaluating Codexis's ECO Synthesis Manufacturing Platform to enhance the production of therapeutic siRNA.
What innovations does the ECO Synthesis platform introduce?
The ECO Synthesis platform replaces traditional synthesis methods with an enzyme-catalyzed approach designed for improved scalability and efficiency.
Who are the key executives mentioned in the partnership announcement?
The key executives include Stephen Dilly, MBBS, PhD, CEO of Codexis, and Tammy Cooper, President at Nitto Denko Avecia.
What is Codexis's role in this collaboration?
Codexis provides its innovative ECO Synthesis platform and collaborates with Nitto Denko to explore scalable manufacturing solutions.
What are the benefits of collaborating with Nitto Denko Avecia?
Nitto Denko Avecia brings extensive expertise in therapeutic oligonucleotide manufacturing, which can help in the wider adoption of new technologies in therapeutic development.
